Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV‑2.

MLA

Maxwell, Joshua W. C., et al. “Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV‑2.” ACS Infectious Diseases, vol. 10, no. 9, Sept. 2024, pp. 3419–29. EBSCOhost, https://doi.org/10.1021/acsinfecdis.4c00544.

APA

Maxwell, J. W. C., Stockdale, S., Stewart, E. L., Ashley, C. L., Smith, L. J., Steain, M., Triccas, J. A., Byrne, S. N., Britton, W. J., Ashhurst, A. S., & Payne, R. J. (2024). Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV‑2. ACS Infectious Diseases, 10(9), 3419–3429. https://doi.org/10.1021/acsinfecdis.4c00544

Chicago

Maxwell, Joshua W. C., Skye Stockdale, Erica L. Stewart, Caroline L. Ashley, Lachlan J. Smith, Megan Steain, James A. Triccas, et al. 2024. “Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV‑2.” ACS Infectious Diseases 10 (9): 3419–29. doi:10.1021/acsinfecdis.4c00544.